<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00811759</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000626803</org_study_id>
    <secondary_id>IGR-CSET-2006/1261</secondary_id>
    <secondary_id>IGR-SORAF-TEM ST1</secondary_id>
    <secondary_id>INCA-RECF0818</secondary_id>
    <secondary_id>EUDRACT-2007-00527-18</secondary_id>
    <secondary_id>SCHER-IGR-CSET-2006/1261</secondary_id>
    <secondary_id>BAYER-IGR-CSET-2006/1261</secondary_id>
    <nct_id>NCT00811759</nct_id>
  </id_info>
  <brief_title>Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>Open-label, Single Center, Uncontrolled Phase I/II Study Evaluating the Safety and Maximum Tolerated Dose of Daily Sorafenib Administered in Combination With Prolonged Temozolomide in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as temozolomide, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving sorafenib together with&#xD;
      temozolomide may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of giving sorafenib&#xD;
      together with temozolomide in treating patients with stage III or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety profile and the maximum tolerated dose of sorafenib tosylate and&#xD;
           temozolomide in patients with stage III-IV melanoma. (Phase I)&#xD;
&#xD;
        -  Evaluate progression-free survival at 12 weeks. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate tumor response according to RECIST criteria.&#xD;
&#xD;
        -  Evaluate overall and progression-free survival.&#xD;
&#xD;
        -  Evaluate the effect of treatment on tumor vascularization.&#xD;
&#xD;
        -  Compare the pharmacokinetic profile of temozolomide with and without sorafenib tosylate.&#xD;
&#xD;
        -  Evaluate the number and the role of lymphocytes.&#xD;
&#xD;
        -  Correlate tumor response rate with BRAF mutation status.&#xD;
&#xD;
        -  Correlate response rate with MGMT activity.&#xD;
&#xD;
        -  Compare the efficacy of genomics and proteomics as a means of discovery of serum&#xD;
           biomarkers.&#xD;
&#xD;
        -  Study the prognostic and predictive value of circulating endothelial cells and&#xD;
           circulating endothelial progenitors.&#xD;
&#xD;
      OUTLINE: This is a phase I dose-escalation study followed by a phase II study.&#xD;
&#xD;
      Patients receive oral sorafenib tosylate twice daily on days 1-28 (days 8-28 of course 1) and&#xD;
      oral temozolomide once daily on days 1-7 and 15-21. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients with accessible tumors (cutaneous or sub-cutaneous) undergo biopsies at baseline and&#xD;
      day 28 for analysis of BRAF mutations and MGMT expression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Anticipated">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (Phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival at 12 weeks (Phase II)</measure>
  </primary_outcome>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of unresectable or metastatic melanoma&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  Previously treated or untreated metastatic disease&#xD;
&#xD;
          -  At least one unidimensionally measurable lesion by RECIST criteria by scan or MRI&#xD;
&#xD;
          -  No concurrent brain or CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  PT, INR, and PTT &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases &lt; 2.5 times ULN (&lt; 5 in the case of liver metastases)&#xD;
&#xD;
          -  Amylase and lipase &lt; 1.5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  Normal respiratory, cardiac, and neurological function&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No history of any of the following cardiac conditions:&#xD;
&#xD;
               -  NYHA class II-IV heart failure&#xD;
&#xD;
               -  Coronary disease&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Cardiac arrhythmia requiring treatment with something other than beta-blockers or&#xD;
                  digoxin&#xD;
&#xD;
               -  Severe uncontrolled hypertension&#xD;
&#xD;
          -  No severe active infection &gt; grade 2&#xD;
&#xD;
          -  No epilepsy requiring medical treatment&#xD;
&#xD;
          -  No other cancer except for carcinoma in situ of the cervix, basal cell carcinoma,&#xD;
             superficial bladder tumors, or curatively treated cancer &gt; 3 years ago&#xD;
&#xD;
          -  No HIV or hepatitis B or C positivity&#xD;
&#xD;
          -  No lactase or galactokinase deficiency, galactose intolerance, or disease accompanied&#xD;
             by malabsorption of glucose or galactose&#xD;
&#xD;
          -  No allergy to the study drugs or to dacarbazine&#xD;
&#xD;
          -  Able to swallow medications&#xD;
&#xD;
          -  No patients deprived of liberty&#xD;
&#xD;
          -  No psychological, familial, social, or geographic conditions that would preclude&#xD;
             clinical follow up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior organ transplantation&#xD;
&#xD;
          -  No prior temozolomide or sorafenib tosylate&#xD;
&#xD;
          -  More than 30 days since other prior antitumor chemotherapy, immunotherapy, hormonal&#xD;
             therapy, or investigational agent&#xD;
&#xD;
          -  More than 30 days since prior study drugs&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior biological response modifiers (i.e., filgrastim [G-CSF])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caroline Robert, MD</last_name>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>October 6, 2010</last_update_submitted>
  <last_update_submitted_qc>October 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2010</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

